Stockwinners Market Radar for July 29, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:20 EDT Heard Capital discloses 9.4% activist stake in Anterix - A regulatory 13D filing on Anterix states: "The Reporting Persons purchased the Shares based on the Reporting Persons' belief that the Shares represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Person may deem advisable. On May 28, 2024, Mr. Heard submitted his consent to the Issuer to be named as a director of the Board, and on July 3, 2024, the Issuer filed its definitive proxy statement in connection with its 2024 Annual Meeting of Stockholders, naming Mr. Heard as a director candidate of the Issuer to be elected to the Board at the Annual Meeting. If Mr. Heard is not elected by the Issuer's stockholders at the Annual Meeting, the Reporting Persons may nonetheless work constructively with members of the Issuer's management team and Board in an effort to continue enhancing and maximizing stockholder value. As a result of Mr. Heard being nominated as a director candidate for election to the Board, the Reporting Persons are converting the beneficial ownership filing on Schedule 13G to a filing on Schedule 13D."

20:22 EDT Nuscale Power responds to short-seller report - NuScale Powerissued the following statement in response to a report on July 29, 2024: "Hunterbrook is a known short-seller that has a vested interest in sensationalizing information to manipulate the stock market. The Securities and Exchange Commission has not communicated to NuScale that it is the target of a current or prospective investigation, and the Company is unaware of any reason for such an investigation."

19:50 EDT Sacks Parente Golf Inc trading halted, news pending

17:45 EDT Kaiser Aluminum CEO Harvey buys $200K in shares - Kaiser Aluminum CEO Keith Harvey disclosed the purchase of 2,588 shares of company stock at $77.23 per share on July 29 for a total transaction amount of $199,871.

17:33 EDT Lockheed Martin awarded $120.27M Navy contract modification - Lockheed Martin was awarded a not-to-exceed $120.27M, firm-fixed-price modification to a previously awarded contract. This modification adds scope to procure additional long-lead time materials to support 21 full rate production, Lot Nine, CH-53K King Stallion aircraft. Work is expected to be completed in March 2025. FY24 aircraft procurement funds in the amount of $120.27M will be obligated at the time of award, none of which will expire at the end of the current fiscal year. Naval Air Systems Command is the contracting activity.

17:07 EDT Analyst Andrew Left indicted for alleged scheme to manipulate stock market - The U.S Attorney's Office said in part on Monday afternoon: "A stock analyst and frequent guest on business television news channels has been charged in a 19-count indictment alleging he used his public platform to illicitly profit by manipulating stock market activity and trading contrary to the position he presented to the public, the Justice Department announced today. Andrew Left, formerly of Beverly Hills but who now resides in Boca Raton, Florida, is charged with one count of engaging in a securities fraud scheme, 17 counts of securities fraud, and one count of making false statements to federal investigators.Left is expected to be arraigned in the coming weeks in United States District Court in downtown Los Angeles."This defendant allegedly used his platform as a securities commentator to manipulate the markets and enrich himself in the process," said United States Attorney Martin Estrada. ... According to the indictment returned on Thursday, Left is a securities analyst, trader, and frequent guest commentator on business cable news channels such as CNBC, Fox Business, and Bloomberg Television. He also conducted business under the name "Citron Research," an online moniker he created as a vehicle for publishing investment recommendations. Citron's online presence included a website and a social media account on X, formerly known as Twitter...Knowing that Citron's reputation with investors had the power to move markets, Left allegedly selected a publicly traded company about which he intended to publish commentary with the intention of manipulating its share price. Left prepared commentary about the company for dissemination through Citron. Sometimes, the commentary represented Left's own work. ...The commentary routinely included sensationalized headlines and inflammatory language to maximize the immediate impact their publication would have on the stock market...For example, in November 2018, Left allegedly wrote a portfolio manager about Nvidia (NVDA) a publicly traded technology company based in Santa Clara, California. In the message, Left wrote, "Do you want to make some fast money Put together a thesis why nvda is oversold . . . We can destroy it . . . Just read the analyst notes from this past quarter and assemble the best of the ideas." Later that morning, Left took financial positions in Nvidia, including short-dated call options that expired three days later. Short-dated options can offer quick profits if a stock suddenly moves in the narrow timeframe before expiration....According to the indictment, Left also furthered his scheme by misrepresented his trading positions during public appearances on news programs. After denouncing one company as a "fraud" on CNBC's "Fast Money," for example, Left allegedly falsely claimed to have covered only a "small size" of his position in the company's stock when, earlier that same day, he had already closed out the majority of his position following the publication of commentary through Citron...If convicted, Left would face a statutory maximum sentence of 25 years in federal prison for the securities fraud scheme count, up to 20 years in federal prison for each count of securities fraud, and up to five years in federal prison for the false statements count. The FBI and the United States Postal Inspection Service are investigating this matter." Reference Link

16:53 EDT Lamb Weston's Jurgensen buys over $554K in company shares - Lamb Weston director William Jurgensen disclosed the purchase of 10,000 shares of company stock on July 26, at $55.43 per share, for a total transaction amount of $554,291.

16:47 EDT Parker-Hannifin to divest its North American CFC Division to SK Capital Partners - Parker Hannifin announced it has signed an agreement to divest its North America Composites and Fuel Containment, or CFC, Division to private investment firm SK Capital Partners. With the completion of this transaction the company will have successfully divested businesses and product lines over the past three years that total nearly $450M in annual sales. The transaction is subject to customary closing conditions. Parker's CFC Division is headquartered in Erlanger, Kentucky and has five additional locations in the U.S. and Mexico,with annual sales of approximately $350M. It became part of Parker's Diversified Industrial Segment, North America businesses following the acquisition of Meggitt plc in 2022. CFC is a leading manufacturer of composites, fuel tanks and bladders. Parker has also completed the divestiture of several other businesses or product lines over the past 36 months, including: France Electromechanical Solutions Division; MicroStrain Division; Filter Resources Division; the Calzoni product line; the Industrial Profile Systems product line; and the Indego exoskeleton product line.

16:44 EDT Repligen to acquire Tantti Laboratory of Taoyuan, sees accretion - Repligen announced that it has entered into a definitive agreement to acquire privately-held Tantti Laboratory of Taoyuan City, Taiwan. Tantti has developed a unique portfolio of macroporous chromatography beads to optimize the purification of new modalities including viral vectors, viruses, nucleic acids and other large molecule biologics. The acquisition is expected to be completed in the fourth quarter of this year. The deal is anticipated to be breakeven on adjusted margins and adjusted earnings per share in 2025 and accretive to adjusted margins and adjusted EPS in 2026. The transaction is expected to be completed by year end 2024, subject to the satisfaction of customary closing conditions, including clearance through the Taiwanese regulatory channel.

16:38 EDT Ranger Energy sees modest further improvement in Q3 results - The company said, "Ranger expects modest further improvement in our third quarter results on a consolidated basis and typical seasonality in the fourth quarter, although year end customer behavior is unpredictable in current market conditions. The High Specification Rigs business is expected to grow revenues modestly year over year despite operator activity levels that have continued to decline during 2024. Our Processing and Ancillary Services segment is expected to have a strong third quarter and Wireline segment results have begun to stabilize over the past two months paving the way for a modest improvement in third quarter results. Ranger has deployed a significant amount of its expected annual capital expenditures in the first half of 2024 and expects a declining capital expenditure profile in the back half of the year."

16:35 EDT Allegro MicroSystems closes first of two repurchases for 39M shares from Sanken - Allegro MicroSystems announced that it has completed the closing of the first of two repurchases for a total of 39 million shares of common stock from Allegro's largest shareholder, Sanken Electri all of which will be retired. The closing of the first repurchase was financed by issuing approximately 29 million shares of common stock for $666 million of net proceeds to repurchase approximately 29 million shares from Sanken. The second closing of the repurchase of approximately 10 million shares is expected to be financed through a combination of proceeds from an incremental term loan under Allegro's existing credit agreement and cash on hand. "This share buyback and retirement represent another important milestone in Allegro's journey as a public company. We believe that broader ownership, increased liquidity and improved governance will act as a catalyst for further value creation," said Vineet Nargolwala, President and CEO. Pursuant to the terms of the Share Repurchase Agreement entered into on July 23, 2024, Allegro has agreed to repurchase from Sanken, in a privately negotiated transaction, a total of 39 million shares of common stock at $23.16 per share, which is the public offering price of the primary offering closed on July 26 minus the discount to the underwriters but before transaction expenses and fees payable by Sanken. After giving effect for the repurchase of the full 39 million shares from Sanken, Sanken's ownership in Allegro will decrease from approximately 50.8% to 32.5%.

16:33 EDT Campbell Soup names Jill Pratt as Chief Marketing Officer - Campbell Soup announced the appointment of Jill Pratt as Senior Vice President, Chief Marketing Officer of its Meals & Beverages division, effective July 29, 2024. Pratt will lead the U.S. Consumer Experience team for Campbell's Meals & Beverages division, partnering with the Category and Sales teams to attract new consumers and strengthen customer partnerships.

16:32 EDT CACI awarded $414M unmanned systems order from U.S. Army - CACI "announced that it has been awarded a five-year task order valued at up to $414 million to provide expertise and unmanned systems support to the U.S. Army Combat Capabilities Development Command - Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance, and Reconnaissance Center to enable warfighter rapid response to current and emerging threats. Under the Global Operational Support task order, CACI will deliver in-depth assessments on available technology and inform countermeasure effectiveness in response to critical requirements at the national, tactical, and operational levels. This includes providing technical subject matter expertise, training, and insight into emerging global threats to the U.S. Army and joint force. It will also include providing customer organizations with in-depth research and analysis of technological trends to develop mitigation strategies that support force protection efforts and increase the overall survivability of the force."

16:26 EDT SandRidge Energy signs definitive agreement for acquisition in Anadarko Basin - SandRidge Energy announced the entry into a definitive agreement to acquire certain producing assets and leasehold interests in the Cherokee play of the Western Anadarko Basin for cash consideration of $144M, before customary purchase price adjustments. The Company also entered into a Joint Development Agreement, or JDA, governing its participation in the future development of certain of the acquired leasehold interests. Acquisition Highlights include: Net production of ~6 MBoed, ~40% oil, focused in Ellis and Roger Mills Counties, Oklahoma; includes 42 producing wells in addition to 4 drilled uncompleted wells scheduled to be turned to production in 2024; immediately accretive to key metrics, including production, EBITDA, and free cash flow; oily PDP production and new development is projected to meaningfully increase SandRidge's EBITDA and cash flow on a pro forma basis, all while maintaining its planned quarterly dividend; leasehold interest in 11 drilling spacing units which add inventory of up to 22 two-mile lateral wells in the highly productive core of the Cherokee play; joint development of DSUs with a partner who has a demonstrable history of successful operations in the Cherokee play; SandRidge will assume operatorship of new wells after they are producing. July 1 effective date with anticipated closing in the Q3. SandRidge plans to fund the transaction with cash on hand. Winston & Strawn is serving as SandRidge's legal advisor for the transaction.

16:22 EDT Renasant to acquire The First Bancshares in all-stock deal valued at about $1.2B - Renasant Corporation (RNST) and The First Bancshares, Inc. (FBMS) jointly announced that they have entered into a definitive agreement and plan of merger, pursuant to which The First will merge with and into Renasant in an all-stock transaction valued at approximately $1.2B, based on Renasant's closing stock price as of July 26, 2024. The Merger has been approved unanimously by each company's board of directors and is expected to close in the first half of 2025. Completion of the transaction is subject to customary closing conditions, including the receipt of required regulatory approvals and the approval of Renasant and The First shareholders. Headquartered in Hattiesburg, Mississippi, The First operates 111 branches across Mississippi, Louisiana, Alabama, Florida and Georgia. As of June 30, 2024, The First had approximately $8.0 billion in total assets, $5.3 billion in total loans and $6.6 billion in total deposits. The Merger will create a six-state Southeastern banking franchise with approximately $25 billion in total assets, $18 billion in total loans and $21 billion in total deposits, based on financial data as of June 30, 2024. "As two of the largest banks headquartered in Mississippi, each with a footprint across the Southeast, both Renasant and The First have grown to know and respect each other's operating philosophy, dedication to providing best-in-class customer service and commitment to the communities in which we operate," said Renasant CEO, Mitch Waycaster. "As with Renasant, The First has expanded into some of the most dynamic, fastest growing markets in the Southeast. Together, we create a more valuable company with the meaningful scale needed to compete in today's operating environment." According to the terms of the merger agreement, shareholders of The First will receive 1.00 share of Renasant common stock for each share of The First common stock. Additionally, all options of The First will be cashed out at their in-the-money value at closing. Based on Renasant's closing stock price of $37.09 per share as of July 26, 2024, the implied transaction value is approximately $37.09 per The First share, or $1.2 billion, in the aggregate. Excluding one-time transaction costs, the merger is expected to be immediately accretive to Renasant's estimated earnings per share and to have a positive long-term impact on Renasant's key profitability and operating ratios.

16:18 EDT Helios Technologies terminates CEO Matosevic - Helios Technologies announced that it has completed the previously announced investigation and determined that Josef Matosevic violated Company policy and demonstrated behavior that was inconsistent with the Company's shared values and Code of Business Conduct and Ethics, which included a consensual personal relationship between Mr. Matosevic and an employee. The violation of Company policy did not involve financial misconduct, or the integrity of the Company's financial systems or controls. The Board has terminated Mr. Matosevic as President, Chief Executive Officer and Board member without severance for cause and is initiating a comprehensive search process to identify a permanent successor. The process will include internal and external candidates. Sean Bagan had previously been appointed to serve as Interim President and Chief Executive Officer in addition to his role as Chief Financial Officer, and Philippe Lemaitre as Executive Chairman in addition to his role as Chairman. Both will continue in these roles while the search is underway.

16:16 EDT Sprouts Farmers Market jumps 11% to $94 after Q2 earnings beat, guidance raise

16:13 EDT Sprouts Farmers Market reports Q2 SSS up 6.7%

16:11 EDT Fluor awarded contract for next phase of FEED work at SMR facility in Romania - Fluor Corporation announced that it has signed a contract with RoPower Nuclear for Phase 2 front-end engineering and design work at its small modular reactor facility in Doicesti, Romania. Fluor will recognize the contract as a new award in the third quarter of 2024. Fluor completed Phase 1 FEED work in the fourth quarter of 2023. The project will utilize NuScale Power's SMR technology to generate carbon-free power, marking a significant milestone in Romania's advancement of clean energy initiatives. A contract signing ceremony took place during the Partnership for Transatlantic Energy and Climate Cooperation summit in Bucharest, Romania, on Wednesday, July 24. The event was attended by Fluor and NuScale representatives, as well as Romanian Minister of Energy Sebastian Burduja and U.S. Secretary of Energy Jennifer Granholm, emphasizing bilateral cooperation and the critical role of SMR technology in addressing carbon free power needs and enhancing energy security. The project has received substantial support from both the Romanian and U.S. governments.

16:11 EDT Celldex's presents results for barzolvolimab in CIndU, ColdU and SD - Celldex Therapeutics announced positive topline results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria or CIndU-cold urticaria, ColdU, and symptomatic dermographism or SD. The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them-exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD. "Barzolvolimab is the first drug in development to demonstrate statistically significant and clinically meaningful results in a large, randomized, placebo-controlled study in chronic inducible urticaria. These data are unprecedented and clearly demonstrate that barzolvolimab has the potential to become a critically needed new treatment option for patients suffering from this disease," said Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics. Data from the 196 patients randomized in the study showed that barzolvolimab achieved the primary efficacy endpoint, a statistically significant difference between the percent of patients with a negative provocation test compared to placebo at Week 12 as assessed by the TempTest in ColdU and the FricTest in SD. Importantly, barzolvolimab demonstrated rapid, durable and clinically meaningful responses in patients with CIndU refractory to antihistamines. Demographics and baseline disease characteristics were well balanced across treatment groups.

16:10 EDT Amneal receives FDA approval for potassium phosphates injection IV bags - Amneal Pharmaceuticals announced that it has received New Drug Application approval from the U.S. Food and Drug Administration for its new presentation of potassium phosphates in 0.9% sodium chloride injection intravenous ready-to-use bags. This sterile presentation reduces the compounding steps for clinicians typically required with administering the product. Potassium Phosphates in Sodium Chloride Injection is a phosphorus replacement product indicated as a source of phosphorus to correct hypophosphatemia in adults and pediatric patients who weigh 40 kg or greater when oral or enteral replacement is not possible, insufficient or contraindicated. The product is available as a single-dose infusion bag and is formulated without preservatives. It is natural rubber latex-free and can be stored at room temperature. In 2024, Amneal has already launched PEMRYDI RTU, a ready-to-use formulation of pemetrexed, and FOCINVEZ, a ready-to-use version of fosaprepitant. Both products offer hospitals and oncology clinics new, value-added presentations that should improve pharmacy efficiency by eliminating preparation steps. The expected third quarter launch of potassium phosphates injection IV bag represents the Company's third 505(b)(2) launch this year. "We are pleased to offer this new differentiated injectable product to hospitals," said Andy Boyer, Executive Vice President, Chief Commercial Officer - Generics. "This new IV parenteral infusion bag is preservative-free and can be stored at room temperature. With the addition of new 505(b)(2) injectables, we are meaningfully expanding our injectables portfolio."

16:04 EDT Air Transport Services delivers two Boeing 767s to Georgian Airways - Air Transport Services Group ( ATSG) announced that its leasing subsidiary Cargo Aircraft Management recently delivered two Boeing (BA) 767-300 aircraft to Georgian Airways LLC of Tbilisi, Georgia under multi-year leases. One of the two Boeing 767-300s is a passenger aircraft delivered in June, while the other is a newly converted freighter delivered in July.

16:03 EDT Air Transport Services delivers two Boeing 767s to

12:43 EDT Pitney Bowes says still working to conclude e-commerce segment reivew - Pitney Bowes noted that on July 26, media outlets reported that the company had sold its entire Global Ecommerce segment. "On the same day, the company's representatives promptly informed these media outlets that the Company had not sold the segment, resulting in full or partial updates to relevant articles." For the "avoidance of doubt," Pitney Bowes released the following statement: "Pitney Bowes is still working to conclude its strategic review of the Company's Global Ecommerce segment. In the meantime, it has sold the segment's fulfillment services business, which is a small piece of the segment."

12:09 EDT Verano to acquire Virginia licenses, Arizona operations from Cannabist Company - Verano Holdings (VRNOF) has entered into agreements to acquire all of the ownership interests of three subsidiaries of The Cannabist Company Holdings (CBSTF), Two subsidiaries, 203 Organix, L.L.C. and Salubrious Wellness Center operate in Arizona, and the third subsidiary, Columbia Care Eastern Virginia LLC, operates in Virginia. Deal Highlights: The Virginia Operations include one cultivation and production facility and six dispensaries. Virginia's cannabis program is uniquely and attractively structured in that the Commonwealth is split into five Health Service Areas with only one cannabis operator and retailer permitted to service each HSA. Verano will become the sole cannabis operator and retailer for HSA 5 in Eastern Virginia. HSA 5 is home to nearly two million residents, serving populated areas such as Virginia Beach, Chesapeake, and Norfolk. Virginia's legal cannabis program permits home delivery throughout the Commonwealth as well as wholesale opportunities to other HSAs, providing Verano the ability to serve patients statewide. Total consideration for the Virginia Operation, subject to adjustment, is $90 million. Upon Closing, Verano will pay closing consideration of $20 million in cash, $40 million in Class A subordinate voting shares, and issue a $30 million promissory note. The Arizona Operations include one cultivation facility, one production facility, and two dispensaries. Verano's total Arizona cultivation footprint will expand to 90,000 square feet across three facilities. Verano will operate eight dispensaries in Arizona adding one in Tempe and one in Prescott. Total consideration for the Arizona Operations is $15 million, payable in cash. Once closed, the acquisitions will bring Verano's geographic footprint to 14 states, 15 cultivation and production facilities, and 150 dispensaries. The Cannabist Company will maintain its Virginia operations in the Richmond region, with approximately 80,000 square feet of cultivation and manufacturing capacity, five retail locations in operation and one in development. Upon exit of the Arizona market, the Cannabist Company's operational footprint will be in 13 markets, including previously announced divestitures that are subject to future closing. Closing of the acquisitions pursuant to the acquisition agreements for the Arizona Operations and the Virginia Operations are each subject to closing conditions, including approval of applicable regulatory bodies.

12:02 EDT Nuscale Power falls -16.1% - Nuscale Power is down -16.1%, or -$1.75 to $9.10.

12:01 EDT Philips rises 13.8% - Philips is up 13.8%, or $3.54 to $29.30.

12:00 EDT Barington Capital calls for TriMas to consider range of strategic alternatives - Barington Capital Group, L.P. and its affiliates, including The Eastern Company (EML), which collectively own approximately 1.5% of TriMas Corporation (TRS), has sent a letter to the Chairman of the Board of TriMas, Herbert Parker, recommending the Company consider a range of alternatives to improve shareholder value. Since the release of Barington's prior letter on December 12, 2023, TriMas has delivered a total shareholder return of +4.6% versus the Company's Proxy Statement peers1 and the Russell 2000, which have delivered total shareholder returns of +26.8% and +19.1%, respectively. James Mitarotonda, Chairman of Barington, said, "Unfortunately, this recent period of underperformance is merely the continuation of what has been a long-term problem. As stated in our prior letter, TriMas' total shareholder return has materially lagged its peers and the market as a whole over the past 1-, 3-, 5-, 7- and 10-year periods. It appears to us that TriMas' multi-segment structure has done little to benefit stockholders." TriMas currently trades at 8.6x NTM consensus EBITDA - a multiple well below what the Company's Packaging and Aerospace segments are worth, according to Barington's analysis. Barington notes that the aerospace sector continues to consolidate due to the robust outlook for travel and defense demand. In addition, a few of TriMas' multi-segment industrial peers have recently been acquired. In both cases, the multiples paid for the target companies were at substantial premiums to TriMas' current NTM consensus EBITDA multiple. For these reasons, Barington sees two compelling alternatives that the TriMas Board should immediately pursue to improve shareholder value - sell the Aerospace segment or sell the entire Company. Mr. Mitarotonda continued, "After many years of attempting to create value for shareholders, which has largely been ineffective, we believe it is imperative that the Board promptly seek value creating alternatives, either by selling the Aerospace segment or the entire Company."

11:57 EDT Dr. Reddy's receives positive CHMP opinion for Rituximab biosimilar - Dr. Reddy's Laboratories announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the launch of its proposed biosimilar Rituximab candidate DRL_RI in European markets. Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance and drug product manufacturing facility located in Hyderabad, India. As part of the established approval process, the CHMP positive opinion will now be reviewed by the European Commission, following which a decision will be made on the grant of marketing authorisation in the European Union member countries, and the European Economic Area member states of Norway, Iceland, and Liechtenstein. A Marketing Authorisation Application (MAA) for submission to the UK Medicines and Healthcare products Regulatory Agency will be made separately in keeping with the reliance route under the International Recognition Procedure.

11:03 EDT Zealand Pharma appoints Eric Cox as CCO - Zealand Pharma announced the appointment of Eric Cox as Zealand's Chief Commercial Officer starting August 5, 2024. Eric will join the executive team to lead Zealand's commercial strategy and assume responsibility for business development. ost recently, Eric was at Carmot Therapeutics, where he led commercial strategy and business development for the obesity and metabolism franchise.

10:00 EDT Coursera falls -6.8% - Coursera is down -6.8%, or -73c to $9.99.

10:00 EDT ZIM Integrated rises 7.3% - ZIM Integrated is up 7.3%, or $1.24 to $18.27.

10:00 EDT Oil States rises 18.1% - Oil States is up 18.1%, or 86c to $5.60.

09:48 EDT 3D Systems falls -5.0% - 3D Systems is down -5.0%, or -19c to $3.61.

09:47 EDT Medical Properties Trust falls -5.7% - Medical Properties Trust is down -5.7%, or -30c to $5.01.

09:47 EDT Philips rises 11.2% - Philips is up 11.2%, or $2.88 to $28.64.

09:46 EDT Baijiayun Group Ltd trading resumes

09:42 EDT University of Texas purchases two additional Knightscope K1 Blue Light Towers - Knightscope announces that the University of Texas purchased two additional Knightscope K1 Blue Light Towers to be installed at a satellite campus in Tyler, Texas. UT has embraced the technology to help provide a safer environment for students, faculty and visitors by making reliable, one-touch access to services such as police, fire and EMS available to everyone on campus.

09:31 EDT Project Energy Reimagined Acqutn Corp trading halted, volatility trading pause

09:25 EDT Petros announces results from analysis of STENDRA self-selection study - Petros Pharmaceuticals announced results of a subsequent analysis of its pivotal study aimed at facilitating FDA-approved OTC access of the Company's STENDRA for consumers. This analysis suggested support for the primary study results and demonstrated improved correct self-selection outcomes resulting from patients using the Company's proprietary Web App Technology and its embedded clinically validated diagnostic tool relative to subsequent verbal interviews that were designed into the study protocol as a form of validation of an ED diagnosis. The analysis shows that men seem to respond with more transparency to clinically validated, yet intimate, erectile diagnostic questions discretely compared to a live interview, illustrating a disparity between the Web App results and the live interview determinations. The initial results from the proprietary technology arm demonstrated a 90.6% Point Estimate and an 86.37% Lower Bound for correct self-selection, while the post hoc analysis demonstrated a 94.9% PE and a 91.51% LB, a rate of self-selection of 4.3% and 5.14% higher, respectively. The statistically significant higher instance of correct self-selection compared to Drug Facts Label utilization alone remained unchanged. These results will be presented to the FDA in support of the results shown in the study in relation to the study endpoints reflected in the study protocol. As reported previously, the study, which evaluated 509 subjects, demonstrated a 90.6% PE correct consumer self-selection for those who used the Company's Web App Technology, compared to 57.3% PE using a DFL alone. Notably, those participants who identified as nitrate users also performed better using the Web App Technology, compared to using DFL alone, a significant difference between the two arms of the study in the high-risk population where Arm B outperformed Arm A by 67%. Although results of the initial analysis were statistically significant showing the separation of the two arms, due to recorded accounts of patient apprehension during the live interviews that followed the patient's discrete entries to the Company's proprietary Web App Technology, several patients were suspected to be mis-diagnosed following the interview portion of the self-selection process, driving the Company to conduct an additional analysis using the Proprietary Web App data alone which also included a clinically validated sexual health survey often used as a standalone diagnostic tool in clinics globally. The post hoc analysis showed improved outcomes of men accurately self-selecting while using only the Proprietary Web App when removing the subsequent interview data. This analysis showed a higher point value of 94.9% correct self-selection, and a lower-bound reading of 91.51%. The pivotal self-selection study was a randomized, 2-arm, open-label, virtual, self-selection study intended to evaluate participant's self-selection with the DFL alone compared to the participant's self-selection with the DFL and the Proprietary Web App Technology. Based on the FDA Proposed Rule for a Nonprescription Product with an Additional Condition of Nonprescription Use the sponsor must "demonstrate that the labeling alone... is insufficient to ensure appropriate self-selection or appropriate actual use, or both." Therefore, the results of this randomized, 2-arm pivotal all-comers self-selection study are intended to provide critical evidence required by the FDA.

09:20 EDT McDonald's says 'good awareness' of value platform - Says more work needed to expand, refine value offerings. Says $5 meal deal performed exactly as anticipated, starting to drive traffic to locations, no effect on sales yet. Says losing share in France, plans to launch 4-EURO happy meal. Says China a "very competitive" market, consumer sentiment "quite weak." Says holding share in China.

09:17 EDT Mullen Automotive announces purchase of CAMPUS EVs by DB Schenker - Mullen Automotive announces that DB Schenker has purchased four Mullen CAMPUS electric vehicles for use on Intel's technology campus in Chandler, Arizona, for mail and package delivery. Randy Marion Automotive, one of Mullen's commercial vehicle dealers, is in receipt of payment and has delivered the vehicles to DB Schenker.

09:12 EDT Cyclo Therapeutics granted patent by European Patent Office - Cyclo Therapeutics announced that the company received a notice from the European Patent Office of a decision to grant European patent application No. 19805439.7 titled, "Methods for Treating Alzheimer's Disease" under European patent number 3873604B. The notice states that mention of the decision will be published on August 21 in European Patent Bulletin 24/34 and will take effect on that date.

09:11 EDT INmune Bio announces new Phase 1 study data on XPro - INmune Bio presents results of a new and advanced proteomic analysis at this year's annual Alzheimer's Association International Conference in Philadelphia, PA. The poster summarizes dose-related changes in the cerebrospinal fluid proteome in patients with Alzheimer's disease treated with XProTM in the company's phase 1b study. The formation and elimination of synapses is executed by cells of the innate immune system such as astrocytes. When these cells are in a dysregulated inflammatory/immune state, synapse formation is reduced and synapse elimination is increased, resulting in loss of communication between neurons which, in the case of AD, results in cognitive impairment. Restoring synapses requires a normally functioning innate immune system.

09:09 EDT Aspira Women's Health appoints John Ragard to board of directors - Aspira Women's Health announced the appointment of Mr. John Ragard to its Board of Directors. John Ragard spent over 46 years as a venture capital investor, public equity buy-side analyst, and portfolio manager. Mr. Ragard is currently a Senior Investment Advisor at Wayve Capital Management after having been a portfolio manager at Spouting Rock for over six years, where he co-managed a small-cap growth portfolio that outperformed the benchmark over the 5-year and since-inception periods.

09:07 EDT LeddarTech obtains additional waiver under credit facility - LeddarTech Holdings entered into a Tenth Amending Agreement with Federation des caisses Desjardins du Quebec with respect to the Amended and Restated Financing Offer dated as of April 5, 2023. As previously announced by the Company on July 5, 2024, pursuant to a Ninth Amending Agreement to the Desjardins Credit Facility, the Company was required to maintain an unencumbered cash balance of C$3.5 million from July 5, 2024 through July 6, 2024, and C$1.8 million from July 7, 2024 through July 26, 2024. Pursuant to the Waiver, among other things, Desjardins has temporarily reduced the required Minimum Cash Covenant to C$1.3 million from July 26, 2024 through August 5, 2024, after which time the Company will be obligated to maintain a minimum cash balance of C$5.0 million.

09:06 EDT LPL Financial: Rizza Financial joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisor Jerry Rizza has joined LPL Financial's broker-dealer, RIA and custodial platforms. He reported having served approximately $250 million in advisory, brokerage and retirement plan assets and joins LPL from Osaic. With 31 years of financial services experience, Rizza's unique background includes playing professional baseball within the Oakland A's minor league system followed by more than three years as an accountant at a CPA firm in New York City. Based in Melville, NY, about 30 miles from New York City, Rizza is joined at Rizza Financial Services by two highly valued, longtime licensed assistants Rachel Beneventano and Jessica Weich. Rizza specializes in retirement planning and behavioral investment counseling, and he enjoys helping clients accrete wealth and harvest income for a more comfortable retirement.

08:59 EDT McDonald's says consumer eating at home more often, seeking more deals - Says consumer sentiment in most major markets "remains low." Says demand falling among families in Europe. Says needs a "broader value platform" to attract more consumers. Says facing a more difficult environment than anticipated last year. Says pressure on industry and consumer is broad-based in nature and has intensified.

08:55 EDT OSI Systems announces $10M order - OSI Systems announced that its security division received an order from an international customer for approximately $10M to provide the company's Z Backscatter Van cargo and vehicle inspection systems including follow on maintenance, training and support. These inspection systems are expected to be deployed for border customs applications.

08:52 EDT McDonald's says taking 'forensic approach' regarding offerings - Says many markets remain "pressured." Expects industry challenges to persist near term. Says "less confident consumer" in China hurt results.

08:46 EDT Foresight Autonomous collaborates with Higer, XJTLU for autonomous buses - Foresight Autonomous Holdings announced the signing of an agreement for a paid proof of concept project with Xi'an Jiaotong-Liverpool University, China's largest Sino-foreign cooperative university. The project aims to install and integrate Foresight's QuadSight technology into Higer Bus Company autonomous buses. The project scope is to jointly develop advanced multi-sensor perception fusion and visualization modeling technology specifically designed for autonomous driving applications. The technology will be initially implemented on Higer's autonomous electric buses. Foresight's QuadSight 3D perception capabilities, combining visible-light and thermal cameras, will be used to accurately detect objects surrounding the vehicle in challenging environmental and weather conditions.

08:43 EDT Hyliion signs LOI to provide 200kW KARNO generator for RNG fueling station - Hyliion Holdings announced the signing of a non-binding letter of intent LOI with U.S. Energy alternative fuels, and environmental credits. Under the terms of the LOI, Hyliion will place a 200kW KARNO generator at a U.S. Energy renewable natural gas fueling station to ensure reliable and efficient power at the site. U.S. Energy's RNG fueling stations are leading the way in enabling natural gas adoption in the commercial transportation sector. Integrating Hyliion's KARNO generator will enhance the station's energy efficiency and contribute positively to U.S. Energy's sustainability goals. "We are excited to collaborate with U.S. Energy, a company that shares our commitment to advancing sustainable energy solutions," said Thomas Healy, Founder and CEO of Hyliion. "The KARNO generator's versatility and efficiency make it an ideal fit for U.S. Energy's RNG station, helping to reduce emissions and optimize energy use." The LOI between Hyliion and U.S. Energy is subject to the execution of a binding purchase agreement.

08:40 EDT BM Technologies launches rewards engine for BankMobile Vibe Checking Account - BM Technologies announced the launch of a rewards engine to its BankMobile Vibe Checking Account. Powered by Kard, the first rewards-as-a-service API, this innovative rewards engine aims to financially empower customers while driving loyalty among customers, giving them the opportunity to earn cash back on debit card purchases from national, online, and local locations.

08:39 EDT Bank of Marin reports Q2 EPS 6c, consensus 17c - As previously announced, the Bank sold 56% of its available-for-sale securities portfolio at an after-tax loss of $22.9 M . Redeployment of the $292.6M net proceeds is expected to provide a 30 basis point increase in annualized net interest margin and 46c per share estimated annualized earnings accretion beginning in the third quarter, assuming an average reinvestment yield of 5.75%. The sale is part of our strategy to improve future earnings and increase return on equity. Excluding the loss on security sales, net income and diluted earnings per share for the second quarter would have been $1M and 6c, all other factors unchanged. A $5.2M provision for credit losses on loans in the second quarter, compared to a provision of $350 thousand for the previous quarter, brought the allowance for credit losses to 1.47% of total loans, compared to 1.24% as of March 31, 2024. The provision was largely due to an increased individual reserve for one non-owner occupied commercial real estate loan totaling $16.7 million that, although current, has experienced a deteriorating financial condition and a material increase in its loan-to-value ratio associated with a recent valuation of the underlying collateral.

08:39 EDT NRx Pharmaceuticals announces alignment with FDA on study plan for NRX-100 - NRx Pharmaceuticals announced a communication from the FDA providing feedback and alignment on NRx's proposed initial Pediatric Study Plan, or iPSP, for NRX-100 - ketamine - in the treatment of suicidal depression. Congress required the submission of an iPSP as a precondition to filing a NDA in the 2012 Food and Drug Administration Safety and Innovation Act. In support of its upcoming NDA filing, NRx will be submitting existing data supporting the safety and efficacy of ketamine to treat suicidal depression in adults. Based on the guidance received, NRx and HOPE Therapeutics will commit to conducting a clinical trial of NRX-100 in adolescents aged 9-17 with suicidal depression, but will not be required to study the effects of NRX-100 in younger age groups, following initial approval of NRX-100 in adults. Additional neurotoxicity studies will be conducted in juvenile animal subjects to support the safety of intravenous ketamine in this younger population.

08:39 EDT Verizon Business awarded $77.5M task order to modernize NWS intrastructure - Verizon Business, a long-term trusted partner of the National Weather Service, NWS, has been awarded a task order valued at nearly $80 million to transition the NWS's current voice and data services from the Networx contract to the Enterprise Infrastructure Solutions vehicle. The transition will help support the NWS's mission-critical work by providing weather, water and climate data, forecasts, warnings and impact-based decision support services.

08:36 EDT Palisade Bio completes microbiome study on PALI-2108 - Palisade Bio announced the successful completion of a microbiome study demonstrating that beta-glucuronidase is present at similar levels among dog, mouse, and human microbiota as well as within healthy humans and those with Crohn's disease and ulcerative colitis. Publicly available data for dog, mouse, and human whole genome metagenomic sequencing was obtained from the NCBI Sequence Read Archive. These samples were found by searching for metagenomic data for the specific host species and further filtered for Illumina paired-end whole genome sequencing data. These data samples were subsampled to 6 million reads each to allow for accurate functional pathway and gene identification while keeping the maximum number of samples for comparison. Company advancing toward commencement of Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end

08:35 EDT Carmell Therapeutics appoints Bracken-Ferguson as CEO - Carmell announced the appointment of Kendra Bracken-Ferguson as Chief Executive Officer effective July 30, 2024 with Rajiv Shukla continuing to serve as Executive Chairman of the Company. Under Kendra's leadership, Carmell aims to accelerate the growth of its flagship brand, Carmell Secretome and expand its portfolio of beauty and wellness brands through strategic investments and acquisitions. The Company was also added to the Russell Microcap Index in June 2024.

08:33 EDT INNOVATE Corp. announces extension of effective data for reverse stock split - INNOVATE that the Company is amending the effective date for its 1-for-10 reverse stock split of the Company's common stock, par value $0.001 per share. The reverse stock split will become effective at 5:00 p.m. Eastern Time on August 8, 2024, after close of trading on the New York Stock Exchange. Previously, the Company planned for the reverse stock split to become effective on August 2, 2024. The Company's Common Stock is expected to begin trading on a split-adjusted basis when the markets open on August 9, 2024, under the existing trading symbol "VATE". The primary goal of the reverse stock split is to increase the per share market price of the Company's Common Stock to meet the minimum per share bid price requirement for continued listing on the NYSE. The reverse stock split was approved by the Company's stockholders at its annual meeting of stockholders held on June 18, 2024. As a result of the reverse stock split, every ten shares of the Company's Common Stock issued and outstanding will be automatically reclassified and changed into one new share of the Company's Common Stock. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's outstanding equity awards, as applicable, as well as to the number of shares issuable under the Company's equity incentive plans and conversion of the Company's outstanding convertible securities. The Common Stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the number of authorized shares of Common Stock or the par value of the Common Stock. Computershare, the Company's transfer agent, is acting as the exchange agent for the Reverse Stock Split. Stockholders holding their shares electronically in book-entry form will not need to take any action. Stockholders holding certificated shares will be required to turn in their existing certificates, and all new shares will be issued in book-entry form, unless such stockholder requests otherwise.

08:31 EDT Hesai enters strategic partnership with Westwell - Hesai Technology announced that it has entered into a strategic partnership with Westwell, a global provider in autonomous driving solutions, to provide lidar in applications including autonomous driving, industrial robots, heavy machinery, and smart cities. Westwell's autonomous driving solutions will be equipped with Hesai's advanced lidar products and serve over 200 corporate clients across 20 countries. Westwell's collaboration with Hesai will also bring higher productivity to the supply chain, significantly enhancing efficiency and quality while reducing carbon emissions on a global scale.

08:22 EDT AMC Entertainment posts highest weekend attendance, admissions revenue of 2024 - AMC Entertainment announced that this past Thursday through Sunday, the company set new 2024 records for weekend attendance and admissions revenue at its AMC Theatres locations in the U.S. and also for its Odeon Cinemas locations throughout the world. In all, AMC and Odeon welcomed more than 6M moviegoers to its theatres from Thursday through Sunday. The weekend performance was led by a record-breaking opening weekend from Disney and Marvel's "Deadpool & Wolverine," which set new all-time opening weekend records for a rated-R film with a media-reported $205M domestically across the industry. Looking at its domestic business, "Deadpool & Wolverine" also set new opening-weekend highs for a rated-R film at AMC's U.S. locations, most notably the highest ever attendance and highest ever admissions revenue for a rated-R film. The company posted its highest food & beverage revenue for a single weekend since 2019, driven in part by record sales at the MacGuffins bars located in about two-thirds of AMC's U.S. theatres. In the U.S., AMC sold more beer, wine, and cocktails during the Thursday-Sunday weekend than in any other weekend in AMC company history. Also popular with guests was the Deadpool & Wolverine merchandise, which was completely sold out during the weekend. "Deadpool & Wolverine" is now AMC's second highest merchandise program in AMC company history.

08:18 EDT Masimo: SafetyNet RPM reduces readmission and ED visits post surgery - Masimo announced the findings of a prospective study published in the Journal of Orthopaedics in which Dr. Michael DeRogatis and colleagues at St. Luke's University Health Network SLUHN in Pennsylvania, joined by researchers at several additional institutions, evaluated the impact of remote patient monitoringor RPM, using Masimo SafetyNet and a hospital's virtual response center VRC on 30-day readmission rates for patients undergoing acute postoperative recovery after total joint arthroplasty TJA . Masimo SafetyNet, a remote patient management and telehealth platform, pairs with a variety of Masimo and third-party devices to seamlessly transmit home-based patient data to hospital clinicians. The researchers found that patients who were remotely monitored after being discharged had significantly lower rates of hospital readmission and ED visits. They concluded, "Remote home monitoring with a virtual response team after outpatient TJA is a feasible way to mitigate readmissions in the acute postoperative period and increase patient satisfaction." ...The authors concluded, "As total joint replacements are increasingly being performed in the outpatient setting, postoperative patient monitoring from home is a feasible way to help mitigate readmissions in the postoperative period. The utility of a virtual response center would be to identify, in real time, certain patient metrics that could indicate potential complications and ultimately allow for more timely intervention that may prevent morbidity and readmissions. Efforts to minimize costs should not be implemented at the expense of patients' health outcomes with a goal to find an appropriate balance between both agendas."1 Masimo SafetyNet is not intended to be used for real-time monitoring.

08:16 EDT WillScot Mobile Mini combines portfolio of brands under WillScot - WillScot Holdings is combining all of its constituent brands - including Mobile Mini - under a unified WillScot brand. In selecting WillScot, the Company leans into both its 80-year legacy as the pioneer of modular and mobile space solutions and its modern-day industry leadership. The updated brand encompasses a streamlined logo and new tagline that embodies WillScot's expertise, reliability, innovation, and partnership in delivering space solutions: Logo - the Company is utilizing the existing WillScot logo which, from the founding of Williams Mobile Offices in the 1940s, has long been recognized for modular space solutions. Since the 2020 merger with Mobile Mini and subsequent expansion into climate-controlled storage, protective buildings and clearspan structures, WillScot has become synonymous with all forms of temporary spaces and turnkey solutions. Tagline - the Company's new tagline is "Right From the Start" and embodies how, from day one, WillScot's local, dedicated experts partner with customers to make their vision a reality. It's a commitment to customers that WillScot brings the expertise and execution required to deliver space solutions that are right for the project, right for the timeline, Right From the Start. For shareholders, the tagline reaffirms WillScot's determination and proven ability to create value by driving growth and innovation, sustainably, for nearly eight decades. In conjunction with rebranding, WillScot is launching a new digital experience with www.WillScot.com. The website offers users an intuitive visual journey to identify space solutions that are optimal for their unique needs and industries. It also consolidates constituent sites, including www.MobileMini.com, into a one-stop digital platform that simplifies access to WillScot's complete offering. The website is the first of several new tools coming from WillScot, as the Company enhances its digital experience for customers. In conjunction with the rebranding announcement, the WillScot parent company also changed its name from "WillScot Mobile Mini Holdings, Corp." to "WillScot Holdings Corporation."

08:14 EDT DZS to demonstrate remote in-band management capabilities at Fiber Connect - DZS announced another milestone in its mission to revolutionize the business case for coherent optics deployment at the network edge. The company will demonstrate what it believes is the world's first remote in-band management capabilities for next-generation 100G/400G optical transport on its industry-leading Saber 4400 platform during Fiber Connect 2024 in Nashville July 29 and 30 at booth number 521.

08:14 EDT Assure Holdings announces further extension of exchange offer - Assure Holdings has extended the expiration date of its exchange offer relating to the Company's 9% Convertible Debentures due 2023 and 2024. As a result of the extension, the Exchange Offer is now scheduled to expire at 11:59 p.m., on August 2, 2024 unless further extended. The Offer was originally scheduled to expire at 11:59 p.m. on July 19, 2024, and was initially extended on July 22, 2024 to expire at 11:59 p.m., on July 26, 2024. Except for the extension of the Expiration Date, all of the other terms of the Offer remain as set forth in the Offer Letter dated June 21, 2024, as amended on July 3 and July 12, 2024, and a Schedule TO related thereto, as filed with the U.S. Securities and Exchange Commission on June 21, 2024, as amended on July 3, July 9, July 12, and July 22, 2024. As of 11:59 p.m. on July 26, 2024, $2.4 million in principal face amount of Assure Convertible Debentures have been tendered into the Offer.

08:12 EDT iCAD, Windsong Radiology announce strategic commercial agreement - iCAD announced a strategic agreement with Windsong Radiology Group, one of US Radiology Specialists, Inc.'s national network of premier providers of diagnostic imaging services located in Western New York. This relationship aims to implement iCAD's ProFound AI Breast Health at Windsong Radiology center locations.

08:11 EDT AEye in $50M common stock purchase agreement With New Circle - AEye announced that it has entered into a common stock purchase agreement with New Circle Principal Investments or New Circle , an affiliate of New Circle Capital. Under the terms of the Purchase Agreement, AEye will have the right, but not the obligation, to sell to New Circle up to $50M of AEye's common stock from time-to-time over the 36-month term of the Purchase Agreement .... Matt Fisch, AEye CEO, said, "We are pleased to announce this stock purchase agreement with New Circle, which could significantly extend our cash runway and enable us to advance our strategic growth initiatives. The establishment of this facility is timely as we have recently reached key performance milestones with our ultra-long range, high-speed lidar product, Apollo, which we believe is the most compact lidar solution for the $5 B ADAS market. Apollo continues to attract significant interest from partners and OEMs who are seeking a value-driven, ultra-long-range lidar solution that addresses safety at speed. Apollo can achieve these standards without requiring OEMs to sacrifice design due to the product's small form factor.

08:09 EDT Cerence collaborates with smart on AI-powered in-car experience - Cerence announced its collaboration with smart, the new-premium all-electric automobile brand, on the development of AI-powered solutions for smart's next-generation in-car experiences, first available in the Concept #5. smart has always kept a keen focus on emerging technology and remained at the forefront of exploring the best solutions for future urban mobility. In the AI era and with the support of Cerence, smart will create a new generation of future-proof, convenient and sustainable solutions for customers, ensuring an outstanding user experience and setting new industry benchmarks in Europe and other overseas markets outside Mainland China.

08:08 EDT Alumis initiates patient dosing in ONWARD Phase 3 trial - Alumis announced that patient dosing has commenced in the ONWARD Phase 3 clinical program. This Phase 3 program consists of two identical 24-week global Phase 3 clinical trials designed to evaluate the efficacy and safety of ESK-001 in adult patients with moderate-to-severe plaque psoriasis and includes a long-term extension trial, ONWARD3, that will evaluate durability and maintenance of response and long-term safety.

08:07 EDT Asset Entities regains compliance with Nasdaq - Asset Entities announced that the Company received formal notice (the "Notice") from the Nasdaq Office of General Counsel of The Nasdaq Stock Market indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

08:06 EDT RTX's Raytheon awarded two Mentor Protege agreements from Dept. of Navy - Raytheon, an RTX business, was awarded two strategic Mentor-Protege Agreement initiatives from the Department of the Navy Office of Small Business Programs to support the development of operational Artificial Intelligence for Department of Defense platforms and programs. Through joint sponsorship from NAVAIR and the Office of Naval Research, Raytheon will mentor Anacapa Micro Products, Inc. and Nara Logics, Inc. Under two individual three-year contracts, Raytheon will provide mentorship for operational AI on system design, software architecture, systems integration, IT security constraints and authority-to-operate requirements in a collaborative environment.

08:06 EDT Corteva increases quarterly dividend 6% to 17c per share - Corteva has authorized a common stock dividend of 17c per share, representing an annual increase of more than 6% over the company's previous quarterly dividend and payable September 17 to shareholders of record on September 3.

08:03 EDT Achieve Life Sciences announces $20M loan refinancing - Achieve Life Sciences has entered into a $20 million debt refinancing agreement with Silicon Valley Bank. The new loan agreement refinances the existing debt facility with SVB and SVB Capital and extends the maturity date from August 1, 2024 to December 1, 2027. Under the terms of the new agreement, the $20 million term loan facility is structured into three tranches, with the first tranche of $10 million received at loan closing. The second tranche of $5 million will be available upon the U.S. Food and Drug Administration's acceptance of filing the New Drug Application for cytisinicline, and the final $5 million tranche will be available at SVB's discretion and subject to SVB's credit committee approval. Under the terms of the agreement, the outstanding principal will accrue interest at a floating rate per annum equal to the greater of 7.0% and the prime rate minus 1.0%. The loan facility includes an interest-only period through December 31, 2025, followed by 24 monthly payments of principal plus interest through the maturity date of December 1, 2027. Additional provisions include the option for a six-month extension to the interest-only period and maturity date upon achieving certain regulatory and financial milestones. Subject to certain terms and conditions, the initial outstanding debt may be converted into shares of Achieve's common stock at SVB's election at any time prior to repayment of such debt, at a conversion price equal to $7.00 per share, subject to customary adjustment provisions. Subsequent tranches may be converted at a conversion price calculated based on a premium to the closing price of Achieve's stock at the applicable time, with a minimum conversion price of $4.854 per share. While the loan remains outstanding, SVB is not permitted to short sell or engage in any other hedging transaction with respect to Achieve's common stock. Achieve has the right at any time to repay and retire all of the outstanding convertible debt prior to its conversion by payment of a premium determined based on the date of such repayment.

08:02 EDT GARR selects Infinera's GX Series ICE6 800G coherent solution - Infinera announced that GARR selected Infinera's GX Series ICE6 800G coherent solution to double capacity of GARR's new optical infrastructure, GARR-T. As part of this project, GARR's expanded network will now extend to Sardinia. The deployment of Infinera's solution across GARR's terrestrial network as well as over the submarine cable system operated by Sparkle strengthens GARR's high-performance optical backbone, facilitating high-speed collaboration between research institutions and universities at the national and international level.

07:46 EDT ZyVersa Therapeutics announces publication of data on inflammasome ASC - ZyVersa Therapeutics announces that inflammasome researchers from the University of Miami Miller School of Medicine and inventors of Inflammasome ASC Inhibitor IC 100 have published a scientific paper in the peer-reviewed International Journal of Molecular Sciences demonstrating that plasma levels of inflammasome ASC show promise as a biomarker of early cognitive decline in older adults. The paper titled, The Inflammasome Adaptor Protein ASC in Plasma as a Biomarker of Early Cognitive Changes, summarizes biomarker assessments in older adults at baseline and at one-year follow-up. Following is a summary of key findings: Plasma ASC levels were elevated in older adults who were cognitively normal at baseline but demonstrated cognitive decline one year later compared to ASC levels in those who remained cognitively normal one-year post-baseline assessment. The increase in ASC levels was even higher in people who were 70 years or older. Likewise, plasma ASC levels in the NI group were elevated compared to ASC levels in older adults who demonstrated cognitive impairment at both baseline and one year later, indicating that plasma ASC levels are increased in the early stages of cognitive decline. Again, the increase in ASC levels was even higher in people who were 70 years or older. In the group over 70 years old, area under the curve for plasma levels of ASC in group NI versus group NN was 0.81, indicating excellent ability to differentiate between people with cognitive decline at one year versus those who were cognitively normal both at baseline and at one year. AUC is used to determine the diagnostic power of a biomarker.

07:38 EDT eDreams Odigeo announces Barcelona court issues measures against Ryanair - eDreams Odigeo, or eDO, said it welcomed the interim measures issued against Ryanair, which mandates an immediate halt to its practices. The company said, "This pre-trial order by the Barcelona Commercial Court No. 12 is based on compelling evidence that Ryanair has engaged in a long-term smear campaign against the Company and its Prime programme, disseminating multiple false claims to mislead consumers and compete unfairly, in violation of Article 9 of the Unfair Competition Law (LCD). The Court has acknowledged the urgent need to approve the measures due to Ryanair's ongoing denigrating statements against eDreams and its products. The judge has determined that Ryanair's lies against eDreams and eDreams Prime are a "perfectly organised campaign designed to promote Ryanair.com for booking flights and associated services". According to this ruling, this campaign is denigrating advertising as it gives consumers false information about eDreams and eDreams Prime. This decision builds on a previous definitive ruling, confirmed by the Spanish Supreme Court, which had already mandated the airline to halt its denigration tactics and anti-competitive behaviour towards eDreams ODIGEO. Ryanair's defamation strategy, which has also targeted multiple other online travel agents, aims to coerce competitors into signing anticompetitive and anti-consumer distribution agreements. This tactic is also intended to deflect scrutiny from Ryanair's own abusive practices and ongoing investigations by authorities across Europe."

07:37 EDT Redwire in MOU with CSS for 'pursuit' of task orders under NASA's REMIS-2 deal - Redwire announced that it has signed a memorandum of understanding, MOU, with Consolidated Safety Services, CSS to jointly pursue future task orders under NASA's $478M Research, Engineering & Mission Integration Services-2 or REMIS-2, contract to support the International Space Station, ISS. Through this MOU, CSS will team with Redwire to compete for task orders to provide spaceflight hardware, ground hardware and software, engineering services, payload facility integration, and research mission integration operations services for the ISS Program under the REMIS-2 contract. As a trusted developer of critical hardware and technology systems spanning more than three decades of human spaceflight, Redwire is an optimal partner to deliver engineering services support for the ISS Program. ..Redwire owns nine payloads and facilities, currently installed on the ISS, designed to conduct critical life and physical science research for commercial and government customers. Additionally, Redwire has managed three NASA-owned research facilities, including material science furnaces and the Advanced Plant Habitat, under a similar space station services contract.

07:34 EDT Telix announces opening of expanded access program in U.S. for TLX101-CDx - Telix Pharmaceuticals announces the opening of an expanded access program in the United States for TLX101-CDx, an investigational positron emission tomography agent for imaging progressive or recurrent glioma, following U.S. Food and Drug Administration agreement to proceed. Amino acid PET is included in U.S. and European clinical practice guidelines for the imaging of gliomas, however there is no FDA-approved targeted amino acid PET agent for brain cancer imaging currently available in the U.S. Telix's goal is to make this product commercially available in the U.S., significantly increasing patient access to this important imaging agent for both adult and paediatric patients. The Company expects to file its New Drug Application for TLX101-CDx with the FDA during Q3 2024.

07:33 EDT Arcutis Biotherapeutics launches ZORYVE cream - Arcutis Biotherapeutics announced the commercial launch of ZORYVE cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age 6 in the United States. ZORYVE is a once-daily, steroid-free cream that provides rapid disease clearance and significant reduction in itch, and was developed to provide long-term disease control. ZORYVE cream 0.15% will be available in pharmacies this week. ZORYVE cream is listed as a line extension within two commercial PBM contracts, providing immediate insurance coverage for many patients.

07:32 EDT Venus Concept announces regulatory approval for Venus Bliss MAX - Venus Concept announced that it has received a medical device license issued by Health Canada to market the Venus Bliss MAX system in Canada. The Venus Bliss MAX was first available in the United States in early 2022 and subsequently offered in approved jurisdictions around the world. The Venus Bliss MAX is a 3-in-1 body shaping solution featuring three of Venus Concept's market leading technologies in one complete platform, including diode laser for Fat Reduction treatments

07:20 EDT AstraZeneca: Fixed-duration CALQUENCE study shows improvement in PFS for CLL - Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca's CALQUENCE or acalabrutinib in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival PFS compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia vor CLL. For the secondary endpoint of overall survival OS , a trend was observed in favor of CALQUENCE in combination with venetoclax, with or without obinutuzumab, versus standard-of-care chemoimmunotherapy. The OS data were not mature at the time of this analysis and the trial will continue to assess OS as a key secondary endpoint. Jennifer R. Brown, MD, PhD, Director of the CLL Center of the Division of Hematologic Malignancies, Dana-Farber Cancer Institute, and the Worthington and Margaret Collette Professor of Medicine at Harvard Medical School, and principal investigator of the trial, said: "The AMPLIFY results demonstrate the potential of acalabrutinib and venetoclax with or without obinutuzumab to be effective and well-tolerated fixed-duration treatment options for patients with chronic lymphocytic leukemia. This is an important advance in this setting as fixed-duration regimens allow those living with this chronic disease to take breaks from their treatment, thereby decreasing the possibility of long-term adverse events and drug resistance and improving quality of life."

07:15 EDT Northern Oil and Gas announces $150M share repurchase program, to raise dividend - NOG's board of directors approved a new $150M common stock repurchase authorization, replacing its prior authorization which was substantially depleted. Per company policy, interim modifications to the dividend can be driven by material changes in realized commodity prices, significant corporate actions or other events, prior to the company's planned annual dividend review during the first quarter of a given fiscal year. Management intends to submit a request to the board of directors for a 5%, or 2c, mid-year increase to NOG's quarterly common stock dividend, to $0.42 per share, for the third quarter of 2024. The company said, "The recommendation is driven by strong cash flow experienced year-to-date and a robust business outlook, combined with the confidence in the cash flows to be provided by NOG's pending acquisitions, Under Delaware law, the Board may not approve dividends more than 60 days before the record date."

07:13 EDT McDonald's: U.S. Q2 SSS driven by negative comparable guest counts - In Q2: U.S.: Comparable sales results were driven by negative comparable guest counts, partly offset by average check growth due to strategic menu price increases. Successful restaurant level execution and continued digital and delivery growth positively contributed to results. International Operated Markets: Segment performance was impacted by negative comparable sales across a number of markets, driven by France. International Developmental Licensed Markets: The continued impact of the war in the Middle East and negative comparable sales in China more than offset positive comparable sales in Latin America and Japan.

07:12 EDT Enstar Group to be acquired by Sixth Street for $338.00 per share in cash - Enstar Group Limited (ESGR) announced that it has entered into a definitive merger agreement under which Sixth Street (TSLX) will acquire Enstar, with Liberty Strategic Capital, J.C. Flowers & Co. LLC, and other institutional investors participating in the transaction. Enstar shareholders will receive a total of $338.00 in cash per ordinary share of Enstar payable upon closing of the transaction, representing a total equity value of $5.1 billion. The consideration represents a premium of approximately 8.5% to the 90-day volume weighted average price of the company shares as of July 26, 2024, the last trading day prior to the announcement of the transaction, and 6.9% to the 60-day VWAP as of the same date. Following the close of the transaction, Enstar will maintain its current operations and business strategy. The transaction, which has been unanimously approved and recommended to its shareholders by Enstar's Board of Directors, is expected to close in mid-2025, subject to approval by Enstar's shareholders, regulatory approvals, and other customary closing conditions. The definitive agreement provides that Enstar will undertake a series of transactions in which Enstar shareholders will receive $338.00 in cash per ordinary share of Enstar. The transaction is fully financed, with the full amount of equity being provided by Sixth Street, together with its co-investors, and Enstar agreeing to return approximately $500 million from its balance sheet to its shareholders as part of the total $338.00 in cash per ordinary share received by shareholders of Enstar. The agreement includes a 35-day "go-shop" period expiring on September 2, 2024, which permits Enstar's Board of Directors and advisors to solicit alternative acquisition proposals from third parties. There can be no assurance that this "go-shop" will result in a superior proposal, and Enstar does not intend to disclose developments with respect to the solicitation process unless and until it determines such disclosure is appropriate or is otherwise required. Enstar will have the right to terminate the merger agreement to enter into a superior proposal both during and after the "go-shop" period, subject to the terms and conditions of the merger agreement. Upon completion of the transaction, Enstar's common stock will no longer be publicly listed, and Enstar will become a privately-held company. The Company will continue to operate under the Enstar name.

07:11 EDT Bio-Techne investing in Spear Bio - 1Bio-Techne announced its participation in Spear Bio's $45M Series A funding round. Spear Bio will use the proceeds from this funding round to further accelerate product development and scale its in-house manufacturing capacity. Bio-Techne joined Foresite Capital, and other investors, in this funding round. Founded in 2021 and headquartered in Woburn, Massachusetts, Spear Bio is involved in the development and manufacture of ultra-sensitive immunoassays capable of measuring protein biomarkers at attomolar level from sub-microliter sample volume. The initial offering will focus on key biomarkers supporting translational research in Alzheimer's disease.

07:11 EDT BiomX announces NYSE American acceptance of plan to regain listing compliance - BiomX announced that it received a notification from the NYSE American, dated July 23, 2024, stating that the NYSE American has accepted the Company's previously submitted plan to regain compliance with the NYSE American's listing standards. In the Acceptance Letter, the NYSE American confirmed that it has granted the Company until November 23, 2025 to regain compliance with the continued listing standards. As previously disclosed, on May 23, 2024, BiomX received a deficiency letter from the NYSE American indicating that the Company was not in compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide.

07:08 EDT Rapport Therapeutics to present data on RTX-1738 - Rapport Therapeutics announced that the Company will present preclinical data on RTX-1738, an analog to Rapport's lead product candidate RAP-219, across a variety of acute and chronic pain models at the upcoming International Association for the Study of Pain, IASP, 2024 World Congress on Pain taking place August 5-9, 2024, in Amsterdam, Netherlands. RTX-1738 demonstrated analgesic activity across a broad range of preclinical pain models. Similar to Rapport's lead product candidate RAP-219, RTX-1738 is an AMPAR. RAP-219 is being studied in a Phase 2a trial in patients with drug-resistant focal epilepsy. Rapport intends to initiate Phase 2a trials evaluating RAP-219 in patients with peripheral neuropathic pain and bipolar disorder in the second half of 2024 and in 2025, respectively.

07:06 EDT Cognition Therapeutics reports proof-of-concept Phase 2 trial outcome - Cognition Therapeutics reported that participants in the proof-of-concept Phase 2 'SHINE' study who were treated with CT1812 for six months showed a consistent trend in cognitive improvement compared to placebo across all cognitive measures including ADAS-Cog 11, ADAS-Cog 13, cognitive composite and MMSE. In addition, there were signals of improvement in functional measures. In this study, CT1812 did not achieve statistical significance on the first of the ordered secondary efficacy endpoints in the pooled 100mg and 300mg dose group compared to placebo. CT1812 demonstrated a favorable safety and tolerability profile with most treatment-related adverse events being mild or moderate, consistent with previous clinical experience. The study showed favorable changes in neurofilament light chain, which is a marker of neurodegenerative disease. These changes were significant at the 300mg dose. The SHINE study achieved its primary objective and demonstrated a favorable safety and tolerability profile, consistent with previous clinical experience. Overall, the percentage of participants experiencing any adverse event was similar between the pooled CT1812 treatment arms and the placebo group. The majority of adverse events were mild or moderate in severity. The most commonly reported treatment-emergent adverse events were infections and infestations, injury, poisoning and procedural complications, gastrointestinal disorders and nervous system disorders.

07:06 EDT Integra Resources to acquire Florida Canyon Gold in C$95M transaction - Integra Resources and Florida Canyon Gold announced that they have entered into a definitive arrangement agreement, dated July 28, whereby Integra has agreed to acquire all of the issued and outstanding shares of FCGI pursuant to a court-approved plan of arrangement. The transaction will create a Great Basin-focused gold and silver producer with immediate gold production of approximately 70,000 ounces of gold equivalent per annum from the Florida Canyon Gold Mine, coupled with a built-in growth pipeline of development stage assets including the DeLamar Project and the Nevada North Project. Under the terms of the transaction, FCGI shareholders will receive 0.467 of a common share of Integra for each common share of FCGI held. Existing shareholders of Integra and FCGI will own approximately 60% and 40%, respectively, of the outstanding Integra shares on closing of the transaction on a fully-diluted in-the-money basis. The exchange ratio implies consideration of C$0.69 per FCGI Share based on the closing market price of the Integra shares on the TSX Venture Exchange on July 26 for total consideration of approximately C$95M. The merger between FCGI and Integra creates a growth focused gold and silver producer in the Great Basin, providing balanced and transformational benefits to shareholders of both Integra and FCGI. Following completion of the Transaction, Integra will hold a diversified and tactically sequenced portfolio of gold-silver production and development assets, all within the top tier mining jurisdiction of the Great Basin. Currently cash flowing Florida Canyon will serve as the foundational production asset, underpinned by two high-quality development projects in DeLamar and Nevada North. The combined portfolio provides a pathway for Integra to materially grow its production profile and become a mid-tier producer capable of delivering over 250kozs AuEq per annum from a top tier mining jurisdiction at a competitive all-in sustaining cost. Pursuant to the transaction, FCGI shareholders will receive 0.467 of an Integra Share for each FCGI Share held. The consideration implies C$0.69 per FCGI share and represents an equity valuation of approximately C$95M based on the closing price of the Integra shares on July 26. Existing shareholders of Integra and FCGI will own approximately 60% and 40% of the combined company, respectively, on a fully-diluted in-the-money basis, before given effect any concurrent financing. The transaction will be effected by way of a court-approved plan of arrangement under the Canada Business Corporations Act, requiring the approval of at least 66% of the votes cast by the shareholders of FCGI voting in person or represented by proxy, if applicable, a simple majority of the votes cast by shareholders of FCGI, excluding for this purpose the votes of "related parties" and "interested parties" and other votes required to be excluded under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions, all at a special meeting of FCGI's shareholders to consider the transaction, and the approval of the Ontario Superior Court of Justice. Directors and senior officers of FCGI have entered into voting support agreements pursuant to which they have agreed, among other things, to vote their FCGI common shares in favour of the transaction. Voting support agreements have also been received from certain FCGI shareholders. On the effective date of the transaction, the board of directors of Integra will be reconstituted such that six current directors of Integra will remain on the board, and Integra will appoint two additional directors from nominees provided by FCGI. In addition to shareholder and court approvals, the transaction is subject to applicable regulatory approvals, including the approvals of the TSXV and the satisfaction of certain other closing conditions customary in transactions of this nature as well as customary interim period covenants regarding the operation of each of the companies' respective businesses. The transaction is subject to the prior completion of the sale of FCGI's Mexican assets, as previously announced, and receipt of approval from the Federal Economic Competition Commission, under the Federal Law of Economic Competition, to such sale. The transaction is also conditional upon binding arrangements being in place for the replacement of collateral supporting the FCGI Surety Bond and release of the Alamos Surety Bond Guarantee. The arrangement agreement contains customary provisions including fiduciary-out provisions in favor of FCGI, non-solicitation and right to match superior proposals in favour of Integra, and a $2.25M termination fee payable to Integra under certain circumstances. Subject to the satisfaction of these conditions, Integra and FCGI expect that the transaction will be completed in the fourth quarter of 2024. Details regarding these and other terms of the transaction are set out in the arrangement agreement. The FCGI shareholder's meeting is expected to occur in October, with closing of the transaction expected in November.

07:05 EDT GSK, Flagship Pioneering announce collaboration - GSK and Flagship Pioneering announced they have entered a collaboration with the goal of discovering and developing a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology. This alliance brings together GSK's disease area expertise and development capability with Flagship's ecosystem of bioplatform companies, inclusive of its novel modalities and technologies, to make major advances in healthcare. GSK and Flagship will initially fund up to $150M upfront to support an exploration phase to identify the most promising concepts for further research and development with Flagship's bioplatform companies. From these explorations, the collaboration aims to identify a portfolio of up to 10 novel medicines and vaccines which will each be subject to an exclusive option by GSK for further clinical development. Under the terms of the agreement, Flagship and its bioplatform companies will be eligible to receive up to $720M in upfront, development and commercial milestones from GSK, as well as preclinical funding and tiered royalties, for each acquired programme.

07:04 EDT Syndax announces PDUFA action date extension for revumenib NDA - Syndax announced that the FDA has extended the Prescription Drug User Fee Act - PDUFA - action date for the New Drug Application - NDA - for revumenib for the treatment of adults and pediatric patients with relapsed or refractory KMT2Ar acute leukemia. The FDA notified Syndax on July 26 that they required additional time to conduct a full review of supplemental information provided to the FDA in response to their requests. The submission of additional information to the FDA was determined to constitute a Major Amendment to the NDA and resulted in a standard three-month extension to the original PDUFA action date of September 26, 2024. No additional trials or manufacturing information have been requested by the FDA. The NDA for revumenib was granted Priority Review and is being reviewed under the FDA's Real-Time Oncology Review program. The FDA previously granted Breakthrough Therapy, Fast Track and Orphan Drug designations for revumenib.

07:02 EDT Compugen's IND for COM503 in solid tumors cleared by FDA - Compugen (CGEN) announced that the FDA has cleared the investigational new drug - IND - application to initiate a Phase 1 trial for COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody licensed to Gilead Sciences (GILD). The IND clearance triggered a $30M milestone payment from Gilead and Compugen is on track to initiate the Phase 1 trial in solid tumors in Q4.

07:02 EDT Eledon enrolls 80th participant in ongoing Phase 2 BESTOW trial - Eledon Pharmaceuticals has enrolled the 80th participant in its ongoing Phase 2 BESTOW trial assessing tegoprubart for the prevention of rejection in kidney transplantation. "As of this week, we have already enrolled two-thirds of the projected study participants across sites in the United States, Europe and Latin America," said David-Alexandre Gros, CEO. "We are grateful to the participants and their clinical teams, whose high level of interest enabled us to achieve this level of enrollment in our Phase 2 BESTOW trial. This progress underscores the urgency and need for innovative solutions in preventing kidney transplant rejection. We remain on track to complete enrollment by the end of the year." BESTOW, a multicenter, two-arm, active comparator clinical study, will enroll approximately 120 participants undergoing kidney transplantation in the United States, Europe and Latin America to evaluate the safety, pharmacokinetics, and efficacy of the anti-CD40 ligand antibody tegoprubart compared to the calcineurin inhibitor tacrolimus. The study's primary objective is to assess graft function at 12 months post-transplant, as measured by estimated glomerular filtration rate, in participants treated with tegoprubart compared to tacrolimus. Better graft function as assessed by eGFR has been associated with improved long-term patient and graft survival.

06:42 EDT Parsons selected as lead designer for Inglewood Transit Connector Project - Parsons will serve as lead designer and a subconsultant to Elevate Inglewood Partners, a public-private partnership consortium comprised of Plenary Americas US, Tutor Perini as lead contractor, Woojin Industrial Systems as automated transit system operator and supplier and Alternate Concepts, as lead operations and maintenance contractor, that has been selected as the Best Value Proposer by the City of Inglewood for the Inglewood Transit Connector Project. The project will include the design, construction, financing, operation and maintenance of a 1.6-mile automated people mover that will connect the Metro K Line and Inglewood's new major employment and destination centers as well as the housing and commercial destinations in the surrounding area. The City has partnered with LA Metro and the County of Los Angeles to establish the ITC Joint Powers Authority, which will oversee the design, construction, operations and maintenance of the ITC following contract award.

06:37 EDT New Gold resumes operations at Rainy River Mine in Ontario - New Gold announced that operations resumed during the day shift on Saturday July 27 at the Rainy River Mine in northwestern Ontario, following the employee fatality reported on July 24. Operations safely resumed Saturday, as no other equipment or site infrastructure was impacted in the incident. New Gold is supporting the authorities with their investigation. The thoughts of management remain with the family, friends and colleagues who have been impacted by this tragic incident. The health, safety and wellbeing of our employees is our top priority.

06:36 EDT Uranium Royalty to acquire additional royalty on Churchrock project for $3.5M - Uranium Royalty announced that it has entered into a binding royalty purchase agreement to acquire an additional royalty on a portion of the Churchrock uranium project owned indirectly by Laramide Resources in New Mexico. The Churchrock project is an advanced stage, ISR uranium project located in the Grants Mineral Belt of New Mexico, 12 miles northeast of Gallup, New Mexico. Laramide has disclosed that the Churchrock Project and nearby properties represent one of the largest and highest-grade undeveloped ISR uranium projects in the United States. The royalty is structured as a gross overriding royalty of 6% "Mine Price", which anticipates recovery of reasonable and actual costs to transport the mineral to the final point of sale. The royalty covers the 10 patented mining claims in Section 8 property that comprise New Mexico Mineral Survey 2220 on the Churchrock Project. Total consideration payable by the company under the transaction is $3.5M, which will be satisfied by the company on closing by paying $1.75M in cash to each of the vendors, each of whom owns an undivided one-half interest in the royalty. The purchase price for the royalty will be funded from cash and liquid assets on hand. The recently released technical report on the Churchrock project highlights a total inferred mineral resource of 50.8M pounds U3O8 for the project, including an Inferred Resource of 10.22 Mlbs U3O8 on Section 8 alone. The preliminary economic assessment is preliminary in nature and includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. There is no certainty that such preliminary economic assessment will be realized. The Churchrock technical report, includes a preliminary economic assessment that estimates a Life of Mine production total of 31.2 Mlbs U3O8, with recovered metal per year of 975,000 pounds U3O8 from the Crownpoint Central Processing Plant, and a mine life of 32 years. Closing of the transaction is subject to, among other things, the satisfaction of customary closing conditions and is expected to occur before the end of July. Each of the vendors owns an undivided one-half interest in a uranium royalty of 6% mine price on part of the S2NE4; part of the E2SW4: part of the SE4NW4 and SE4, Section 8, T16N, R16W, N.M.P.M., McKinley County, New Mexico. The royalty covers the 10 patented mining claims in Section 8 that comprise New Mexico Mineral Survey 2220 on the Churchrock project. The royalty is structured as a gross overriding royalty of 6% "mine price", which anticipates revenues based on contract sales and recovery of certain reasonable and actual costs to transport the mineral to the final point of sale.

06:32 EDT GSK announces EMA CHMP recommended expanding approval of RSV vaccine - GSK announced that the European Medicines Agency's, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended expanding the approval of GSK's respiratory syncytial virus, RSV, vaccine for the prevention of lower respiratory tract disease, LRTD, caused by RSV from adults aged 60 and above to include adults aged 50-59 years at increased risk for RSV disease. Today's positive opinion is the first time that an indication for adults aged 50-59 has been recommended by CHMP for a RSV vaccine, one of the final steps prior to the extension of the marketing authorisation by the European Commission. The European Commission's final decision is expected by September 2024. GSK's RSV vaccine was approved by the US FDA for adults aged 50-59 at increased risk on 7 June 2024. GSK has also filed regulatory submissions to expand the use of its RSV vaccine to adults aged 50-59 at increased risk in Japan and other geographies with regulatory decisions undergoing review.

06:31 EDT Guardant Health's Shield blood test for colorectal cancer approved by FDA - Guardant Health announced the U.S. FDA has approved the company's Shield blood test for colorectal cancer screening in adults age 45 and older who are at average risk for the disease. It is the first blood test to be approved by the FDA as a primary screening option for CRC, meaning healthcare providers can offer Shield in a manner similar to all other non-invasive methods recommended in screening guidelines. Shield is also the first blood test for CRC screening that meets the requirements for Medicare coverage.

06:25 EDT GSK reports confidential settlement with Kimbrow resolving Zantac case - GSK stated: "GSK plc has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court. GSK does not admit any liability in this settlement. The case will now be dismissed as to GSK. Following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders."

06:11 EDT Pearson board raises interim dividend 6% to 7.4p per share - The dividend accounted for in the six months to 30 June 2024 is the final dividend in respect of 2023 of 15.7p. An interim dividend for 2024 of 7.4p was declared by the Board in July 2024 and will be accounted for in the second half of 2024

06:09 EDT Target announces first denim take back event - Target introduced its first chain-wide Denim Take Back Event. From August 4-10, consumers can recycle their used or outgrown denim of any brand in-store and receive 20% off a new denim apparel purchase with Target Circle.

06:08 EDT Textron and Gama Aviation, UK, sign three aircraft deal - Textron announced an agreement with Gama Aviation UK for the purchase of three cargo door-equipped Beechcraft King Air 360C aircraft expected to be delivered in 2025. The deal supports the mission of the Scottish Ambulance Service. Gama Aviation has been a provider of air ambulance services to the SAS for more than 30 years with the King Air as the mainstay of the company's fixed wing fleet.

06:07 EDT Loews CEO James Tisch to transition to chair, Benjamin Tisch to succeed - Loews announced that, as part of its leadership succession plan, on December 31, James Tisch will retire as president and CEO and will be succeeded by Benjamin Tisch, current senior VP, corporate development and strategy. As part of the leadership transition, James Tisch will become chairman of the board of directors, and Benjamin Tisch and Loews Hotels & Co's CEO Alexander Tisch will join the board. Also, Andrew Tisch and Jonathan Tisch will transition from directors to directors emeriti.

05:37 EDT Philips backs FY24 comparable sales growth view 3%-5% - The company said, "Philips reiterates its confidence in delivering the 2025 plan, acknowledging that uncertainties remain. For the full year 2024, Philips continues to expect 3-5% comparable sales growth, an Adjusted EBITA margin of 11-11.5%, and free cash flow of EUR 0.9-1.1 billion. The outlook excludes the potential impact of the ongoing Philips Respironics-related legal proceedings, including the investigation by the US Department of Justice."

05:28 EDT Palantir, TES announce multi-year partnership - Palantir and Tree Energy Solutions, or TES, announced a multi-year partnership to leverage Palantir's AI software in TES's mission to drive the green energy transition and accelerate global decarbonization. Through this partnership, Palantir Foundry and Palantir Artificial Intelligence Platform, or AIP, will support TES in supply chain management, simulation and scenario modeling for investment optimization, site selection, asset management, carbon emissions tracking, and modeling the energy transformation pipeline.

05:18 EDT Elbit Systems awarded $190M supply contract - Elbit Systems announced that it was awarded a contract worth approximately $190M to supply its Iron Sting laser and GPS-guided mortar munition to the Israeli Ministry of Defense. The contract will be performed over a period of two years. Iron Sting is a precision-guided mortar munition, launched from a 120mm mortar, designed to accurately target and destroy objectives, utilizing both immune GPS and laser guidance technology. It has a range of up to 10 kilometers.

05:13 EDT SHL Telemedicine to appoint David Arnon as CEO - SHL Telemedicine has announced that it has appointed David Arnon as CEO of the company. He will join SHL Telemedicine and assume the role on August 6, succeeding Erez Nachtomy, who, as previously announced, will step down as CEO. Arnon has over 17 years of commercial and executive level management experience within the healthcare insurance industry in Israel. He has experience in establishing sales, marketing and operations teams, developing and commercializing products. Arnon joins SHL from Doral Group, a company in renewable energy, where he served as CEO of Doral Mea.

05:04 EDT Lipella Pharmaceuticals enrolls first patients in LP-310 trial - Lipella Pharmaceuticals announced the enrollment of the first patients in its multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus, or OLP. Lipella's Phase 2a trial is a multi-center, dose-ranging study of LP-310, a proprietary liposomal-tacrolimus oral rinse formulation of the company's lead candidate LP-10 for hemorrhagic cystitis. The trial has enrolled its first patients across multiple research sites nationwide, spanning from Philadelphia to San Francisco, and is actively screening additional subjects with symptomatic Oral Lichen Planus.